ActiGraph, the leading provider of medical-grade wearable activity and sleep monitoring solutions, has announced a new partnership with data analytics specialist VivoSense. The partnership will enhance the ability of both companies to deliver sponsor access to secure, regulated, analyzed, and contextualized sensor data from patients participating in pharmaceutical clinical trials. VivoSense is a regulatory compliant, cloud based platform for the analysis of wearable sensor data. VivoSense with VivoCapture provides pharmaceutical sponsors with secure access to contextualized sensor data, metadata, analyzed, and raw signals. The platform makes use of Azure authentication and authorization, computing, and storage in a regulated sensor data warehouse.
ActiGraph’s class-leading wearable activity monitoring sensors provide pharma companies with unparalleled levels of continuous, high-resolution physiologic data. The collection and accurate analysis of these biometric data streams is vital in today’s clinical research and helps to accelerate study enrollment and patient engagement.
VivoSense can analyze data from any biometric sensor or combination of sensors to integrate, clean, analyze, and derive new biomarkers that withstand the most rigorous academic and regulatory scrutiny. The large physiological data-sets generated by these sensors are key to monitoring health and understanding the effects of new medicines and therapies in development.
"Providing context to collected wearable sensor data empowers our clients to make better sense of the data and investigate novel disease endpoints,” said Dudley Tabakin, CEO and Co-founder of VivoSense. "Combining ActiGraph’s world-leading activity and sleep monitoring with other physiological measures, cleaned and analyzed by VivoSense, will provide important context to all clinical trials measures.
VivoSense, founded in 2009, and based in Newport Coast, CA, is a leader in wearable sensor monitoring technology for clinical research. Through the use of VivoSense core laboratory services and VivoSense technology, pharmaceutical researchers can now obtain high quality data solutions to continually and passively describe a patient's longitudinal status in clinical, ambulatory and home settings. VivoSense has supported research and clinical trials using VivoSense at over 500 leading pharmaceutical, research and academic institutions across a wide range of disease states, including sleep disordered breathing, congestive heart failure, chronic obstructive pulmonary disease, Rett Syndrome and cystic fibrosis. For more information, visit www.vivosense.com.
ActiGraph is a leading provider of medical-grade physical activity and sleep monitoring solutions for the global scientific community. ActiGraph’s FDA-cleared wearable actigraphy monitors and robust analytics platform have been widely used to quantify human movement in academic and population health research for nearly two decades. In recent years, the company’s monitoring solutions have been steadily adopted by pharmaceutical and life sciences organizations seeking to capture real-world objective outcomes related to physical activity, mobility, and sleep behavior for patients enrolled in clinical trials. For more information, visit www.actigraphcorp.com.